These observations and our in vitro findings suggest that pharmacological approaches based on the modulation of KSR2 activity could represent a novel potential therapeutic strategy for the treatment of obesity and type 2 diabetes. The gene discussed is KSR2; the disease is obesity due to melanocortin 4 receptor deficiency.